Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C12H16N4O3.ClH |
Molecular Weight | 300.741 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OC[C@H]1CN(CC2=CNC3=C2N=CNC3=O)C[C@@H]1O
InChI
InChIKey=CMKFYLGNPVHLJV-RJUBDTSPSA-N
InChI=1S/C12H16N4O3.ClH/c17-5-8-3-16(4-9(8)18)2-7-1-13-11-10(7)14-6-15-12(11)19;/h1,6,8-9,13,17-18H,2-5H2,(H,14,15,19);1H/t8-,9+;/m1./s1
Ulodesine (BCX4208) is a new, orally active, highly potent inhibitor of purine nucleoside phosphorylase (PNP) for the treatment of hyperuricemia and gout. Inhibition of PNP reduces the substrates available for XO to form uric acid. The drug is currently under development for the management of hyperuricemia in chronic gout. Two Phase II clinical trials have shown promising results regarding urate-lowering effect in both as monotherapy and in combination with allopurinol. Ulodesine shows no interaction with CYP450 isoforms and has no hepatic metabolism; therefore, no drug interactions were expected. Following the successful outcome of the Phase IIb clinical trial, Phase III development of ulodesine is planned. One concern regarding the use of ulodesine is its impact on T cells. Lack of PNP is associated with immunodeficiency and autoimmune disorders.
Approval Year
Sample Use Guides
In the 12-week randomized controlled trial, in
82 gout patients, the response rates to 5, 10, 20 and 40 mg ulodesine (BCX4208) compared with allopurinol 300 mg were 45, 33, 39 and 49%, respectively
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.invivochem.com/ulodesine-bcx4208/
Ulodesine is a novel and potent inhibitor of purine nucleoside phosphorylase (PNP) with an IC50 of 0.5 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID20210563
Created by
admin on Fri Dec 15 15:40:50 GMT 2023 , Edited by admin on Fri Dec 15 15:40:50 GMT 2023
|
PRIMARY | |||
|
DBSALT002180
Created by
admin on Fri Dec 15 15:40:50 GMT 2023 , Edited by admin on Fri Dec 15 15:40:50 GMT 2023
|
PRIMARY | |||
|
615580-53-5
Created by
admin on Fri Dec 15 15:40:50 GMT 2023 , Edited by admin on Fri Dec 15 15:40:50 GMT 2023
|
PRIMARY | |||
|
O0JCK72YU4
Created by
admin on Fri Dec 15 15:40:50 GMT 2023 , Edited by admin on Fri Dec 15 15:40:50 GMT 2023
|
PRIMARY | |||
|
135565454
Created by
admin on Fri Dec 15 15:40:50 GMT 2023 , Edited by admin on Fri Dec 15 15:40:50 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD